Top Medical News

CMSC 2022: Top Interviews and Key Takeaways

June 27, 2022

By Matt Hoffman

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Zolgensma Further Demonstrates Impact in Treating Presymptomatic SMA, Regardless of 2 or 3 SMN2 Copies

June 27, 2022

By Marco Meglio

In total, 100% and 93% of those in the SMN two- and three-copy cohorts achieved the primary end point of sitting independently for at least 30 seconds after 18 months of treatment.

Decompressive Craniectomy Shows Greater Improvements in Traumatic Intracranial Hypertension Than Standard Treatment

June 27, 2022

By Marco Meglio

Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.

This Week on NeurologyLive® — June 27, 2022

June 27, 2022

By NeurologyLive® Staff

Here's what is coming soon to NeurologyLive®.

NeurologyLive® Brain Games: June 26, 2022

June 26, 2022

By Matt Hoffman

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Featured

Mind Moments Podcast

Click here to listen to Mind Moments™, a podcast from NeurologyLive® that brings you exclusive interviews with expert neurologists and clinicians.

NeuroVoices

Click here to read NeurologyLive®'s NeuroVoices series of in-depth, exclusive conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.

Coverage of the Advanced Therapeutics in Movement and Related Disorders Congress

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor.

Coverage of the SLEEP Annual Meeting

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor.

Brain Games

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics.

Coverage of the American Headache Society Annual Scientific Meeting

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor.

Latest Videos

MS COVID-19/Vaccine Advice

Novel Oral Treatment Selection in RRMS

Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis

Involving Patients in the Conversation About Parkinson Disease Treatment Approaches: Jill Farmer, DO, MPH

Evobrutinib, BTK Inhibitors, and the Associations With Neurofilament Light: Jens Kuhle, MD, PhD

Using Primseq to Simplify the Complexities of Rehabilitation Intervention Dosing: Heidi Schambra, MD

Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH

AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight

Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD

Improving Post-Stroke Rehabilitation Through Primseq Digital Tool: Heidi Schambra, MD

The ATMRD Congress and Importance of Accessibility as a Clinician: Jill Farmer, DO, MPH

AAN Expert Exchange: Sphingosine-1 Phosphate Modulation in MS

AAN Expert Exchange: Advances in Progressive Multiple Sclerosis

Most Recent

Phase 2b Study of Parkinson Disease LRRK Inhibitor BIIB122 Initiated

June 25, 2022

Article

BIIB122, a selective central nervous system-penetrant small molecule inhibitor of LRRK2 is expected to be evaluated in a cohort of 640 patients with early-stage Parkinson disease.

Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications

June 24, 2022

Article

At least 2 weeks following Evusheld injection, all 18 patients included in the cohort had the highest level of antibody response.

NeurologyLive® Friday 5 — June 24, 2022

June 24, 2022

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns

June 24, 2022

Article

The decision to stop clinical testing of SRP-5051 in DMD follows a serious adverse event of hypomagnesemia in part B of the phase 2 MOMENTUM trial.

Eplontersen Meets Primary, Secondary End Points in Phase 3 Trial for hATTR Polyneuropathy

June 24, 2022

Article

Based on the 35-week interim trial results, AstraZeneca and Ionis will seek regulatory approval for eplontersen and plan to file a new drug application with the FDA in 2022.

Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease

June 23, 2022

Article

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

Biogen Terminates Phase 4 ICARE-AD Trial of Aducanumab in Alzheimer Disease

June 23, 2022

Article

The trial was terminated because of the expectation of enrollment not being feasible, driven by the recent CMS national coverage determination. The phase 4 confirmatory ENVISION trial is still ongoing.

Tofersen Continues to Show Promising Clinical, Biomarker Results in SOD1-ALS

June 23, 2022

Article

Both the early- and delayed-start tofersen treatment groups demonstrated reductions in SOD1 protein, the intended target for tofersen, and neurofilament, a marker of axonal injury and neurodegeneration.

Reformulating Rofecoxib for the Acute Treatment of Migraine

June 23, 2022

Article

Bradford C. Sippy, the chief executive officer of Tremeau Pharmaceuticals, spoke about the company’s work to reformulate rofecoxib, known now as TRM-201, to treat acute migraine.

Updates in Dravet Syndrome: Entering a New Era

June 23, 2022

Article

Progress in therapeutics and diagnosis over the past decade has dramatically shifted the treatment landscape for this genetic epilepsy and rapidly advanced patient care.

Latest SAP Content

CMSC 2022: Top Interviews and Key Takeaways

Involving Patients in the Conversation About Parkinson Disease Treatment Approaches: Jill Farmer, DO, MPH

Using Primseq to Simplify the Complexities of Rehabilitation Intervention Dosing: Heidi Schambra, MD

Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH

View More SAP Content